IBB News 249.30 06/11/2014 05:04:50 Nasdaq Biotechnology Ishares

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nasdaq Biotechnology Ishares (IBB) 249.30 $IBB

Two Biotech ETFs Surge on Idenix-Merck Deal - ETF News And Commentary
Sweta Killa - ZACKS - Tue Jun 10, 1:00PM CDT
Idenix Pharmaceuticals pushes these two biotech ETFs higher ahead of the rivals on Merck buyout.

Jim Cramer's 'Mad Money' Recap: Fewer Jobs = Bull Market
at The Street - Wed Jun 04, 7:10PM CDT
Disbelief is a hallmark of a powerful bull market, Cramer says. Nowhere is that disbelief stronger than in the notion that fewer jobs are better for stock prices.

iShares Nasdaq Biotechnology Index Rises 1.06% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jun 04, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $239.34 to a high of $243.72. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $241.59 on volume of 906,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Look Abroad When You Have an American Trendless Market
at The Street - Tue Jun 03, 1:11PM CDT
You can't judge this market by the headlines. But India is showing much greater potential.

A Comprehensive Guide to Biotech ETFs - ETF News And Commentary
Zacks Equity Research - ZACKS - Fri May 30, 7:00AM CDT
Despite recent volatility in the space, the longer-term fundamentals remain attractive.

SmarTrend Watching for Potential Pullback in Shares of iShares Nasdaq Biotechnology Index After 2.48% Gain
Comtex SmarTrend(R) - Tue May 27, 4:18PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $236.60 to a high of $240.68. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $236.28 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

After Yesterday's Rally of 2.48% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue May 27, 4:17PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $236.60 to a high of $240.68. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $236.28 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

iShares Nasdaq Biotechnology Index Fund (IBB) : Stop activated ($239.00)
Trading Central - Tue May 27, 10:00AM CDT
The ETF has reached our stop loss which was set at $239.00. Performance: -5.55%. Trading strategy: Stop activated ($239.00).

How Will Biotech Fare the Rest of the Year?
George Budwell, The Motley Fool - Motley Fool - Fri May 23, 5:30PM CDT
Biotech has had a fairly volatile year thus far. Shares of the closely watched iShares Nasdaq Biotech Index , for instance, have swung from double-digit gains to high single-digit losses at one point this year. With the index now roughly flat for...

iShares Nasdaq Biotechnology Index Set to Possibly Pullback After Yesterday's Rally of 1.92%
Comtex SmarTrend(R) - Thu May 22, 3:43PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $229.00 to a high of $236.28. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $231.96 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

iShares Nasdaq Biotechnology Index Fund (IBB) : Short Sell @ $226.44
Trading Central - Thu May 15, 10:33AM CDT
From a technical view, the ETF is shaping a symmetrical triangle calling for the continuation of the previous bearish trend. Regarding technical indicators, the daily MACD is facing a strong resistance area while the daily RSI is reversing down from...

R.I.P. the Momentum Trade, 2012-2014
at The Street - Tue May 13, 1:39PM CDT
The momentum trade is dead. And a new momentum trade has risen to take its place.

iShares Nasdaq Biotechnology Index Fund (IBB) : Close former position at last price ($232.50)
Trading Central - Tue May 13, 9:10AM CDT
On a relative basis against the IVV S&P500, the iShares Nasdaq Biotechnology Index Fund is losing upward momentum since it is reversing down from a bearish trend line; we prefer to close our long position opened on April 22nd. Trading strategy: ...

Watch for iShares Nasdaq Biotechnology Index to Potentially Pullback After Gaining 2.42% Yesterday
Comtex SmarTrend(R) - Mon May 12, 4:06PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $227.09 to a high of $232.40. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $231.14 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 2.42% Rise
Comtex SmarTrend(R) - Mon May 12, 4:03PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $227.09 to a high of $232.40. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $231.14 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Growth Correction Over - Real Time Insight
Kevin Cook - Zacks Investment Research - Mon May 12, 2:00PM CDT
Where are you finding GARP now?
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 445

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 222

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 198

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 216

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 163

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 152

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 306

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 392

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 410

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 314

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading

Top 5 Most Recently Viewed Articles

Globant's 2025 Q1 Revenue Growth and Strategic Focus

Updated Category News Views 873

Globant's Remarkable Financial Performance for Q1 2025 Globant (NYSE: GLOB), a leader in technology-enabled business transformation, has reported a strong performance for the first quarter of 2025. The company achieved revenues of $611.1 million, marking a 7.0% increase compared to the same period last year. This notable growth reflects Globant's commitment to leveraging...

Continue Reading
Transforming Rehabilitation: The Future of Medical Exoskeletons

Updated Category News Views 329

Explosive Growth in the Medical Exoskeleton Market The global medical exoskeleton market is experiencing remarkable growth, projected to reach a value increase of USD 2.87 billion during the upcoming period from 2024 to 2028. A crucial driving force behind this surge is the rising number of spinal cord injury (SCI) cases, coupled with advancements in artificial...

Continue Reading
Exclusive Elks Hoop Shoot Champions Honored at Hall of Fame

Updated Category News Views 167

Celebrating Youth Basketball Talent The spirit of perseverance and hard work was palpable as the finest youth free-throw shooters gathered at Wintrust Arena, illustrating their dedication to the game. Recently, the Elks Hoop Shoot competition showcased young athletes' skills and determination as they vied for national titles in three age groups for both boys and girls....

Continue Reading
Key Insights for Cepton, Inc. Investors Regarding Legal Actions

Updated Category News Views 190

Understanding Your Legal Rights as a Cepton, Inc. Investor Cepton, Inc. (NASDAQ: CPTN) has recently come under scrutiny, attracting the attention of investors concerned about potential securities fraud. As such, it is crucial for shareholders to be informed about their rights and options as they navigate these turbulent waters. Recent developments suggest that investors...

Continue Reading
Teamsters at Seattle Airport Vote to Strike Against Swissport

Updated Category News Views 283

Teamsters at Seattle Airport Take Bold Action In a significant move toward ensuring safe and fair labor practices, air fuelers at Seattle-Tacoma International Airport have voted unanimously to authorize a strike against Swissport, a leading provider of ground services in the aviation industry. With over 150 workers represented by Teamsters Local 174, this decision stems...

Continue Reading